{"filing":{"accession_number":"0001193805-26-000696","cik":"0001280776","ticker":"IMUX","company_name":"IMMUNIC, INC.","form":"8-K","filing_date":"2026-05-27","report_date":null,"primary_document":"e665513_8k-immunic.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1280776/000119380526000696/e665513_8k-immunic.htm"},"events":[{"id":8777,"run_id":7704,"accession_number":"0001193805-26-000696","anchor_item_number":"5.02","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.92,"summary":"Erik Lundgren was appointed as Chief Executive Officer effective June 1, 2026, with a detailed employment agreement including a base salary of $685,000, performance bonuses, and an equity grant of 1,000,000 options. Dr. Daniel Vitt resigned as CEO concurrent with this appointment.","company_name":"IMMUNIC, INC.","ticker":"IMUX","filing_date":"2026-05-27","form":"8-K","submitted_at":null,"items":[{"id":1964,"accession_number":"0001193805-26-000696","item_number":"5.02","item_title":"Departure of Directors or Principal","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.92,"reasoning":"The filing discloses the appointment of Erik Lundgren as Chief Executive Officer effective June 1, 2026, with a detailed employment agreement including base salary of $685,000, performance bonuses, and an equity grant of 1,000,000 options. While the section also mentions Dr. Daniel Vitt's resignation as CEO, the principal disclosed action centers on the appointment of the new CEO and his compensatory arrangements, making exec_appointment the most salient classification.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-28T02:34:19.326662+00:00","company_name":"","ticker":null,"filing_date":""},{"id":1965,"accession_number":"0001193805-26-000696","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.85,"reasoning":"The filing discloses the appointment of Mr. Lundgren as Chief Executive Officer and the resignation of Dr. Vitt. While both events are mentioned, the principal action disclosed is the appointment of a new CEO, which is a material executive change. The CEO appointment is the forward-looking event of primary significance to investors, making exec_appointment the most salient classification despite the concurrent departure.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-28T02:34:19.326662+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":1964,"accession_number":"0001193805-26-000696","item_number":"5.02","item_title":"Departure of Directors or Principal","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.92,"reasoning":"The filing discloses the appointment of Erik Lundgren as Chief Executive Officer effective June 1, 2026, with a detailed employment agreement including base salary of $685,000, performance bonuses, and an equity grant of 1,000,000 options. While the section also mentions Dr. Daniel Vitt's resignation as CEO, the principal disclosed action centers on the appointment of the new CEO and his compensatory arrangements, making exec_appointment the most salient classification.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-28T02:34:19.326662+00:00","company_name":"IMMUNIC, INC.","ticker":"IMUX","filing_date":"2026-05-27"},{"id":1965,"accession_number":"0001193805-26-000696","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.85,"reasoning":"The filing discloses the appointment of Mr. Lundgren as Chief Executive Officer and the resignation of Dr. Vitt. While both events are mentioned, the principal action disclosed is the appointment of a new CEO, which is a material executive change. The CEO appointment is the forward-looking event of primary significance to investors, making exec_appointment the most salient classification despite the concurrent departure.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-28T02:34:19.326662+00:00","company_name":"IMMUNIC, INC.","ticker":"IMUX","filing_date":"2026-05-27"}]}